phosphonoacetic acid has been researched along with Kidney Diseases in 5 studies
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intravenous foscarnet was given on an emergency basis to 30 immunosuppressed patients with cytomegalovirus (CMV) disease, of whom 28 were organ transplant recipients." | 9.06 | Sensitivity of cytomegalovirus to intravenous foscarnet treatment. ( Akesson-Johansson, A; Lernestedt, JO; Lönnqvist, B; Ringdén, O; Wahren, B, 1986) |
| "Intravenous foscarnet was given on an emergency basis to 30 immunosuppressed patients with cytomegalovirus (CMV) disease, of whom 28 were organ transplant recipients." | 5.06 | Sensitivity of cytomegalovirus to intravenous foscarnet treatment. ( Akesson-Johansson, A; Lernestedt, JO; Lönnqvist, B; Ringdén, O; Wahren, B, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Powis, G | 1 |
| Farese, RV | 1 |
| Schambelan, M | 1 |
| Hollander, H | 1 |
| Stringari, S | 1 |
| Jacobson, MA | 1 |
| Deray, G | 1 |
| Katlama, C | 1 |
| Dohin, E | 1 |
| Hollis, LS | 1 |
| Miller, AV | 1 |
| Amundsen, AR | 1 |
| Schurig, JE | 1 |
| Stern, EW | 1 |
| Akesson-Johansson, A | 1 |
| Lernestedt, JO | 1 |
| Ringdén, O | 1 |
| Lönnqvist, B | 1 |
| Wahren, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure[NCT00000691] | Phase 2 | 156 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for phosphonoacetic acid and Kidney Diseases
| Article | Year |
|---|---|
Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs.
Topics: Antineoplastic Agents; Aspartic Acid; Bleomycin; Cisplatin; Cyclophosphamide; Doxorubicin; Fluoroura | 1982 |
1 trial available for phosphonoacetic acid and Kidney Diseases
| Article | Year |
|---|---|
Sensitivity of cytomegalovirus to intravenous foscarnet treatment.
Topics: Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovirus Infections; Female; | 1986 |
3 other studies available for phosphonoacetic acid and Kidney Diseases
| Article | Year |
|---|---|
Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Diabetes In | 1990 |
Prevention of foscarnet nephrotoxicity.
Topics: Adult; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Viral; Female; Fluid Therapy; F | 1990 |
cis-diamineplatinum (II) complexes containing phosphono carboxylate ligands as antitumor agents.
Topics: Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Chromatography, High Pressure Liquid; | 1990 |